Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Epilepsy
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Epilepsy
    TopAbstracts in Epilepsy 06/25/2009 - (DGNews)
    TopAbstracts in Epilepsy 06/11/2009 - (DGNews)
    FDA Approves Once-Daily Extended Release Lamotrigine for Epilepsy - (DGNews)
    TopAbstracts in Epilepsy 05/28/2009 - (DGNews)
    TopAbstracts in Epilepsy 05/14/2009 - (DGNews)

    News archive

     Recent webcasts/CME - Epilepsy
  • Some Anti-Epileptic Drugs May Compromise Bone Health
  • Balancing Treatment With Reproductive Health in Women With Epilepsy
  • Understanding the Ramifications of Switching Among AED's: A 2008 Clinical Update

    Webcasts/CME archive

     Recent cases - Epilepsy
      Diarrhea, Negative T-Waves, Fever and Skin Rash, Rare Manifestation of Carbamazepine Hypersensitivity: A Case Report
      Syncope Due to Asystole During Epilepsy. A Case Report
      Lennox Gastaut Syndrome, Review of the Literature and a Case Report
      Partial Trisomy 13q22-qter Associated to Leukoencephalopathy and Late Onset Generalised Epilepsy
      Probable Causal Link Between Epilepsy and Sleep Apnea: Case Report

      Cases archive
        




      my personal edition > epilepsy > news
      divider

        E-Mail this DGReview to a colleague

      DGReview


      Post-Marketing Surveillance With Gabapentin Reveals Only Previously Documented Neurological Side Effects

      A DGReview of :"A postmarketing surveillance study of gabapentin as add-on therapy for 3,100 patients in England"
      Epilepsia

      10/25/2002
      By Alison Palkhivala


      A post-marketing surveillance of gabapentin found that although the drug caused the expected neurological side effects such as drowsiness, dizziness and lassitude, there were no unrecognized adverse events.

      L. V. Wilton and S. Shakir from the Drug Safety Research Unit, Southampton, England, conducted this on the use of gabapentin as an add-on therapy for the treatment of epilepsy. They identified patients taking gabapentin in this manner from records about dispensing of prescriptions kept by the National Health Service. Approximately six months after the initial prescription, the investigators sent the patients' physicians questionnaires about the patient demographics and use of gabapentin.

      Among the 3,100 patients who comprised the cohort of this observational study, 136 were children. The median duration of gabapentin use among these patients was 8.1 months. The most frequently reported adverse events during the first month of treatment were drowsiness/sedation, dizziness and malaise/lassitude. These adverse events were also the ones most commonly cited as reasons for discontinuing the drug.

      Eleven women in the cohort used gabapentin during the first trimester of their pregnancy, and none gave birth to babies with congenital abnormalities. Crude mortality rate among the patients taking gabapentin was five times that of the general population but no higher than those reported by other studies.
      Epilepsia 2002 Sep;43(9):983-92. "A postmarketing surveillance study of gabapentin as add-on therapy for 3,100 patients in England"

      E-Mail this DGReview to a colleague   To print, use this version






      All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send